165 related articles for article (PubMed ID: 36858505)
21. Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
Fouqueray P; Chevalier C; Bolze S
Clin Drug Investig; 2022 Sep; 42(9):721-732. PubMed ID: 35867199
[TBL] [Abstract][Full Text] [Related]
22. Imeglimin: A Clinical Pharmacology Review.
Chevalier C; Fouqueray P; Bolze S
Clin Pharmacokinet; 2023 Oct; 62(10):1393-1411. PubMed ID: 37713097
[TBL] [Abstract][Full Text] [Related]
23. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.
Hagi K; Kochi K; Watada H; Kaku K; Ueki K
J Diabetes Investig; 2023 Sep; 14(9):1101-1109. PubMed ID: 37264517
[TBL] [Abstract][Full Text] [Related]
24. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
Konkwo C; Perry RJ
Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
[TBL] [Abstract][Full Text] [Related]
25. Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes.
Nowak M; Grzeszczak W
Endokrynol Pol; 2022; 73(2):361-370. PubMed ID: 35381095
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
[TBL] [Abstract][Full Text] [Related]
27. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using
Fauzi M; Murakami T; Fujimoto H; Botagarova A; Sakaki K; Kiyobayashi S; Ogura M; Inagaki N
Front Endocrinol (Lausanne); 2022; 13():1010825. PubMed ID: 36246910
[TBL] [Abstract][Full Text] [Related]
28. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model.
Vial G; Chauvin MA; Bendridi N; Durand A; Meugnier E; Madec AM; Bernoud-Hubac N; Pais de Barros JP; Fontaine É; Acquaviva C; Hallakou-Bozec S; Bolze S; Vidal H; Rieusset J
Diabetes; 2015 Jun; 64(6):2254-64. PubMed ID: 25552598
[TBL] [Abstract][Full Text] [Related]
29. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells.
Vial G; Lamarche F; Cottet-Rousselle C; Hallakou-Bozec S; Borel AL; Fontaine E
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00211. PubMed ID: 33855213
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
31. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.
Perry RJ; Cardone RL; Petersen MC; Zhang D; Fouqueray P; Hallakou-Bozec S; Bolze S; Shulman GI; Petersen KF; Kibbey RG
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E461-70. PubMed ID: 27406738
[TBL] [Abstract][Full Text] [Related]
32. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
Ishibashi R; Hirayama K; Watanabe S; Okano K; Kuroda Y; Baba Y; Kanayama T; Ito C; Kasahara K; Aiba S; Iga R; Ohtani R; Inaba Y; Koshizaka M; Maezawa Y; Yokote K
J Diabetes Investig; 2023 Dec; 14(12):1419-1422. PubMed ID: 37715448
[TBL] [Abstract][Full Text] [Related]
33. The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study.
Oda T; Satoh M; Nagasawa K; Sasaki A; Hasegawa Y; Takebe N; Ishigaki Y
Diabetes Ther; 2022 Sep; 13(9):1635-1643. PubMed ID: 35895275
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
[TBL] [Abstract][Full Text] [Related]
35. Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes.
Doupis J; Baris N; Avramidis K
touchREV Endocrinol; 2021 Nov; 17(2):88-91. PubMed ID: 35118453
[TBL] [Abstract][Full Text] [Related]
36. Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P; Vial G; Fontaine E; Monternier PA; Fouqueray P; Bolze S; Moller DE; Hallakou-Bozec S
Physiol Rep; 2022 Mar; 10(5):e15151. PubMed ID: 35274817
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
[TBL] [Abstract][Full Text] [Related]
38. A review of phenformin, metformin, and imeglimin.
Yendapally R; Sikazwe D; Kim SS; Ramsinghani S; Fraser-Spears R; Witte AP; La-Viola B
Drug Dev Res; 2020 Jun; 81(4):390-401. PubMed ID: 31916629
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
[TBL] [Abstract][Full Text] [Related]
40. Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis.
Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
J Diabetes Res; 2020; 2020():8768954. PubMed ID: 32215274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
